ANP32D

ANP32D
Identifiers
Aliases	ANP32D, PP32R2, acidic nuclear phosphoprotein 32 family member D
External IDs	OMIM: 606878; GeneCards: ANP32D; OMA:ANP32D - orthologs
Gene location (Human)
Chr.	Chromosome 12 (human)
End	48,473,622 bp
RNA expression pattern
	Top expressed in
	sural nerve; ; embryo; ; ganglionic eminence; ; urinary bladder; ; left adrenal gland; ; adrenal cortex; ; left adrenal cortex; ; right adrenal cortex; ; muscle of thigh; ; sigmoid colon;
	n/a
	More reference expression data
	More reference expression data
Gene ontology
Molecular function	histone binding;
Cellular component	nucleus; perinuclear region of cytoplasm;
Biological process	nucleosome assembly; nucleocytoplasmic transport; regulation of apoptotic process; histone exchange;
	Sources:Amigo / QuickGO
Orthologs
	23519
	n/a
	ENSG00000139223
	n/a
	O95626
	n/a
	NM_012404
	n/a
	NP_036536
	n/a
	Wikidata
View/Edit Human

Acidic leucine-rich nuclear phosphoprotein 32 family member D is a protein that in humans is encoded by the ANP32D gene.^[3]^[4]^[5]

Phosphoprotein 32 (PP32) is a tumor suppressor that can inhibit several types of cancers, including prostate and breast cancers. The protein encoded by this gene is one of at least two proteins that are similar in amino acid sequence to PP32 and are part of the same acidic nuclear phosphoprotein gene family. However, unlike PP32, the encoded protein is tumorigenic. The tumor suppressor function of PP32 has been localized to a 25 amino acid region that is absent in the protein encoded by this gene. This gene does not contain introns.^[5]

^ ^a ^b ^c GRCh38: Ensembl release 89: ENSG00000139223 – Ensembl, May 2017
^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^ Kadkol SS, Brody JR, Pevsner J, Bai J, Pasternack GR (Apr 1999). "Modulation of oncogenic potential by alternative gene use in human prostate cancer". Nat Med. 5 (3): 275–9. doi:10.1038/6488. PMID 10086381. S2CID 24559649.
^ Brody JR, Kadkol SS, Mahmoud MA, Rebel JM, Pasternack GR (Aug 1999). "Identification of sequences required for inhibition of oncogene-mediated transformation by pp32". J Biol Chem. 274 (29): 20053–5. doi:10.1074/jbc.274.29.20053. PMID 10400610.
^ ^a ^b "Entrez Gene: ANP32D acidic (leucine-rich) nuclear phosphoprotein 32 family, member D".

[refGRCh38Ensembl-1] GRCh38: Ensembl release 89: ENSG00000139223 – Ensembl, May 2017

[2] "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.

[pmid10086381-3] Kadkol SS, Brody JR, Pevsner J, Bai J, Pasternack GR (Apr 1999). "Modulation of oncogenic potential by alternative gene use in human prostate cancer". Nat Med. 5 (3): 275–9. doi:10.1038/6488. PMID 10086381. S2CID 24559649.

[pmid10400610-4] Brody JR, Kadkol SS, Mahmoud MA, Rebel JM, Pasternack GR (Aug 1999). "Identification of sequences required for inhibition of oncogene-mediated transformation by pp32". J Biol Chem. 274 (29): 20053–5. doi:10.1074/jbc.274.29.20053. PMID 10400610.

[entrez-5] "Entrez Gene: ANP32D acidic (leucine-rich) nuclear phosphoprotein 32 family, member D".

[1]

[2]

[3]

[4]

[5]